MRNA vs NBIX
Moderna, Inc. and Neurocrine Biosciences Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | MRNA | NBIX |
|---|---|---|
| Revenue | $1.9B | $2.9B |
| Net income | $-2.8B | $478.6M |
| Gross margin | 55.3% | 98.2% |
| Net margin | −145.2% | 16.7% |
| Return on equity | −28.9% | 16.4% |
| Diluted EPS | −$7.26 | $4.67 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $-2.1B | $748.7M |
| Equity | $8.7B | $3.3B |
| Net debt / equity | −0.23× | · |
| Current ratio | 3.29× | 3.39× |
| Revenue CAGR 5y | 19.3% | 22.3% |
| Profit CAGR 5y | · | 3.3% |
NBIX bills 1.5× the revenue of MRNA, and MRNA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | MRNA | NBIX |
|---|---|---|
| FY2025 | $1.9B | $2.9B |
| FY2024 | $3.2B | $2.4B |
| FY2023 | $6.8B | $1.9B |
| FY2022 | $19.3B | $1.5B |
| FY2021 | $18.5B | $1.1B |
| FY2020 | $803.0M | $1.0B |
| FY2019 | $60.0M | $788.1M |
| FY2018 | $135.1M | $451.2M |
| FY2017 | $205.8M | $161.6M |
| FY2016 | $108.4M | $15.0M |
Bottom line
| Fiscal year | MRNA | NBIX |
|---|---|---|
| FY2025 | $-2.8B | $478.6M |
| FY2024 | $-3.6B | $341.3M |
| FY2023 | $-4.7B | $249.7M |
| FY2022 | $8.4B | $154.5M |
| FY2021 | $12.2B | $89.6M |
| FY2020 | $-747.0M | $407.3M |
| FY2019 | $-514.0M | $37.0M |
| FY2018 | $-384.7M | $21.1M |
| FY2017 | $-255.9M | $-142.5M |
| FY2016 | $-216.2M | $-141.1M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$916,500,000 | NBIX |
| FY2024 | +$880,700,000 | MRNA |
| FY2023 | +$4,960,900,000 | MRNA |
| FY2022 | +$17,774,300,000 | MRNA |
| FY2021 | +$17,337,500,000 | MRNA |
| FY2020 | −$242,900,000 | NBIX |
| FY2019 | −$728,100,000 | NBIX |
| FY2018 | −$316,132,000 | NBIX |
| FY2017 | +$44,199,000 | MRNA |
| FY2016 | +$93,396,000 | MRNA |
The higher-revenue side has changed between MRNA and NBIX over this period. The gap has widened since the earliest year compared.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −161.9 pp | NBIX |
| FY2024 | −124.5 pp | NBIX |
| FY2023 | −82.1 pp | NBIX |
| FY2022 | +33.0 pp | MRNA |
| FY2020 | −132.0 pp | NBIX |
| FY2019 | −861.4 pp | NBIX |
| FY2018 | −289.5 pp | NBIX |
| FY2017 | −36.1 pp | NBIX |
| FY2016 | +741.1 pp | MRNA |
The higher net margin has changed hands between MRNA and NBIX over this period.
9 of 14 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NBIX's net margin has been more volatile than MRNA's over the 9 comparable fiscal years — 298.1 percentage points of standard deviation against 245.6.
9 of 14 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between MRNA and NBIX over these 9 fiscal years — MRNA led in 2 and NBIX in 7.
9 of 14 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's return on equity has been more volatile than NBIX's over the 7 comparable fiscal years — 64.6 percentage points of standard deviation against 12.7.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between MRNA and NBIX over these 7 fiscal years — MRNA led in 2 and NBIX in 5.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.